Pacific released a research report on April 26 stating that it gave Sunshine Novo (688621.SH) a purchase rating. The main reasons for the rating include: 1) strong clinical business growth throughout the year, with 23Q4 sales expenses dragging down profit growth; 2) continuous increase in R&D investment and continuous expansion of the talent team; 3) high growth in new signings and ongoing orders, and strong certainty about future performance. (Mainichi Keizai Shimbun)
太平洋4月26日发布研报称，给予阳光诺和（688621.SH）买入评级。评级理由主要包括：1）全年临床业务增长强劲，23Q4销售费用拖累利润增速；2）不断加大研发投入，人才队伍持续扩充；3）新签及在手订单高增长，未来业绩确定性强。（每日经济新闻）
Pacific released a research report on April 26 stating that it gave Sunshine Novo (688621.SH) a purchase rating. The main reasons for the rating include: 1) strong clinical business growth throughout the year, with 23Q4 sales expenses dragging down profit
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.